Future directions in atopic dermatitis - 27/05/26

Doi : 10.1016/j.jaad.2026.01.077

Nicholas Stefanovic, MB, BCh, BAO, MSc ^⁎ , Alan D. Irvine, MD, DSc

School of Medicine, Trinity College Dublin, Dublin, Ireland

^∗ Correspondence to: Nicholas Stefanovic, MB, BCh, BAO, MSc, School of Medicine, Trinity College Dublin, Dublin, Ireland. School of Medicine Trinity College Dublin Dublin Ireland

Abstract

Atopic dermatitis is the most prevalent and burdensome inflammatory skin disorder worldwide. Despite significant new insights into disease epidemiology, pathogenesis, and therapeutics over the past decade, significant challenges remain. This article aimed to identify outstanding challenges and suggest where novel innovations are likely to be made to address these.

Le texte complet de cet article est disponible en PDF.

Key words : atopic dermatitis, comorbidities, drug development, global health, prevention

Abbreviations used : AD, EASI, IGA, IL, JAK

Plan

Introduction

Prevention of AD

Comorbidity modification

Achieving deeper therapeutic efficacy in AD

Novel oral therapies, other than JAK inhibitors

Topical therapies beyond topical glucocorticoids

Disease modification

Therapeutic challenges across diverse global settings

	Funding sources: None.
	Author Disclosures: Prof Irvine serves as a paid consultant for AbbVie, Arena Pharmaceuticals, BenevolentAI, Dermavant, Eli Lilly, Genentech, LEO Pharma, Menlo Therapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals Inc, Sanofi, Sitryx, and UCB, is a speaker for AbbVie, Eli Lilly, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals Inc, and Sanofi, is an investigator for AbbVie, Novartis, and Sanofi-Regeneron Pharmaceuticals Inc, and is a patent holder for Regeneron Pharmaceuticals Inc. Dr Stefanovic has no conflicts of interest to declare.
	Reviewer Disclosures: Jonathan Weiss, MD, has disclosed the following relevant relationships — AbbVie (Investigator/Grants & Research Funding, Speaker/Honoraria), Arcutis, Inc. (Consultant/Honoraria, Speaker/Honoraria), Bristol-Myers Squibb (Investigator/Grants & Research Funding, Advisory Board/Honoraria), Dermavant Sciences (Investigator/Grants & Research Funding, Advisory Board/Honoraria, Speaker/Honoraria), Incyte Corporation (Advisory Board/Honoraria), Leo Pharma Inc (Speaker/Honoraria, Consultant/Honoraria), Novartis (Investigator/Grants & Research Funding, Advisory Board/Honoraria), Pfizer Inc. (Speaker/Honoraria), Regeneron (Speaker/Honoraria), Sanofi Genzyme (Speaker/Honoraria), UCB (Consultant/Fees, Advisory Board/Honoraria).
	IRB approval status: Not applicable.
	Dedication: To the memory of Dr Robert Sidbury, who leaves behind a remarkable legacy of patient focused compassionate care, clinical and scientific excellence, and deep collegiality. He is missed.